Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight
View original at globenewswire.comAlcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight New York, USA, June 08, 2026 (GLOBE NEWSWIRE) -- Alcohol Use Disorder Market Set to Expand at a 12.1% CAG…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The United States accounted for the largest alcohol use disorder treatment market size in 2025 compared to EU4, UK, and Japan
60% confidenceThe 12-month diagnosed prevalence of AUD in the US declined from approximately 10.6% in 2021 to approximately 9.7% in 2025
60% confidenceThe AD04 patent, once granted, is expected to protect Adial's core assets through at least 2045
60% confidenceThe exploration of novel mechanisms in AUD treatment such as 5-HT3 antagonism, NOP receptor modulation, mGluR5 NAM activity, and dual GLP-1/glucagon receptor agonism highlights significant opportunities for other developers to enter a space with high unmet need and to differentiate their pipelines through innovative, non-traditional targets
60% confidenceAlthough several AUD therapies have been approved, treatment uptake remains substantially low, leaving a significant proportion of affected individuals untreated
60% confidenceThe AUD market size was USD 1.1 billion across the 7MM in 2025
60% confidenceThe AUD market is projected to expand at a 12.1% CAGR during the forecast period 2026–2036
60% confidenceVIVITROL (naltrexone) holds the highest US AUD market share in 2025, while by 2036, AD04 is projected to capture the largest market
60% confidenceGrowing awareness, early AUD diagnosis, rising focus on harm reduction and personalized care, and strong clinical trial activity are expected to drive significant AUD market growth
60% confidenceAltimmune expects to announce topline results from the RECLAIM Phase II trial evaluating pemvidutide in AUD in 2026
60% confidenceBrenipatide represents Eli Lilly's expansion into indications beyond obesity, including alcohol use disorder, opioid dependence, and asthma
60% confidenceThere were 25.6 million 12-months diagnosed prevalent cases of AUD in the US in 2025, which are projected to decrease by 2036
60% confidence